“The present circumstance has uncovered some structural weaknesses within the EU’s medicines offer chain as well as a large dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides explained. She suggested that offer chain challenges be addressed within an EU pharmaceutical tactic envisioned being launched by the tip